Chemical Structure
Inhibitor
1450 Citations
Trametinib
BT-0020
Trametinib is a highly selective, allosteric MEK1/2 inhibitor approved for BRAF V600E/K-mutated melanoma and NSCLC.
Biological Activity
Inhibits MEK1/2 activation and ERK1/2 phosphorylation, suppressing cell proliferation in MAPK-driven cancers.
Product Specifications
CAS Number871700-17-3
Molecular FormulaC26H23FIN5O4
Molecular Weight615.39 g/mol
TargetMEK1/MEK2
PathwayMAPK/ERK Signaling
Disease AreaCancer
IC50/EC50/KdIC50: 0.7 nM (MEK1), 0.9 nM (MEK2)
Purity>99%
SolubilityDMSO: ≥10 mg/mL
Storage-20°C, desiccated
SpeciesHuman
Available Sizes
| Size | Price | |
|---|---|---|
| 5 mg | $70.00 | |
| 25 mg | $240.00 |